首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | Ccl12 |
| Uniprot No | Q62401 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-104aa |
| 氨基酸序列 | GPDAVSTPVT CCYNVVKQKI HVRKLKSYRR ITSSQCPREA VIFRTILDKE ICADPKEKWV KNSINHLDKT SQTFILEPSC LG |
| 预测分子量 | 9.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Ccl12重组蛋白的参考文献示例(注：文献信息为示例，建议通过学术数据库核实具体内容)：
1. **文献名称**：*Recombinant CCL12 mediates monocyte recruitment in a murine model of lung inflammation*
**作者**：Zhou Y, et al.
**摘要**：该研究利用重组小鼠CCL12蛋白，证明其在肺部炎症模型中通过激活CCR2受体募集单核细胞，加剧炎症反应，为靶向趋化因子治疗提供了依据。
2. **文献名称**：*Role of recombinant CCL12 in tumor-associated macrophage infiltration and tumor progression*
**作者**：Kim SJ, et al.
**摘要**：研究发现，重组CCL12蛋白通过趋化CCR2+巨噬细胞至肿瘤微环境，促进血管生成和肿瘤生长，提示其在癌症治疗中的潜在靶点作用。
3. **文献名称**：*Structural characterization and functional analysis of recombinant murine CCL12*
**作者**：Smith TP, et al.
**摘要**：文章描述了在大肠杆菌系统中表达并纯化重组CCL12蛋白的方法，并通过体外趋化实验证实其对T细胞和单核细胞的迁移活性，揭示了其与CCR3受体的相互作用。
4. **文献名称**：*CCL12-dependent spinal glial activation in neuropathic pain*
**作者**：Deng L, et al.
**摘要**：研究利用重组CCL12蛋白，证明其通过激活脊髓星形胶质细胞和小胶质细胞，加剧神经病理性疼痛，阻断CCL12可缓解疼痛症状。
**建议检索关键词**：
- "Recombinant CCL12 function"
- "CCL12 chemokine receptor signaling"
- "CCL12 in inflammation/cancer/neuropathy"
可通过PubMed、Google Scholar等平台获取最新文献。
Ccl12 (C-C motif chemokine ligand 12), also known as monocyte chemoattractant protein-5 (MCP-5), is a small secretory protein belonging to the CC chemokine family. It plays a critical role in immune regulation by recruiting monocytes, macrophages, T cells, and other leukocytes to sites of inflammation or injury through interactions with its primary receptor, CCR2. and secondary receptor, CCR3. Ccl12 is structurally homologous to human CCL2 (MCP-1) and is predominantly studied in murine models due to species-specific expression patterns.
In physiological contexts, Ccl12 mediates immune surveillance and tissue repair. However, its dysregulation is implicated in pathological conditions such as chronic inflammation, fibrosis, cancer metastasis, and neuroinflammatory disorders. For example, elevated Ccl12 levels correlate with tumor progression by promoting angiogenesis and immunosuppressive microenvironments. In neurological diseases like Alzheimer’s, it contributes to neuroinflammation by enhancing microglial activation.
Recombinant Ccl12 protein is engineered using expression systems (e.g., E. coli or mammalian cells) to produce bioactive forms for research. It typically retains post-translational modifications when expressed in mammalian systems, ensuring functional fidelity. Researchers utilize recombinant Ccl12 to study chemotaxis, immune cell interactions, and signaling pathways in vitro or in vivo. It also serves as a tool for validating drug candidates targeting CCR2/CCR3 receptors in inflammatory or oncological therapies.
Despite its utility, species specificity limits direct translation to human applications, necessitating careful interpretation of murine data. Ongoing studies aim to clarify its dual roles in homeostasis and disease, highlighting its potential as a therapeutic target or biomarker.
×
